EICHOR
● Completed
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
Condition: Retinal Vein Occlusion · Sponsor: Annexin Pharmaceuticals AB
About this study
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (7)
| Eye Associates of Northeast Louisiana | West Monroe, Louisiana, United States | — |
| Cumberland Valley Retina Consultants | Hagerstown, Maryland, United States | — |
| Tulsa Retina Consultants | Tulsa, Oklahoma, United States | — |
| Retina Consultants of Texas | Bellaire, Texas, United States | — |
| Valley Retina Institute | McAllen, Texas, United States | — |
| Retina Consultants of Texas | San Antonio, Texas, United States | — |
| Virginia Retina Center | Warrenton, Virginia, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05532735